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Background: Activating KRAS and BRAF mutations predict unresponsiveness to EGFR-targeting therapies in
colorectal cancer (CRC), but their prognostic value needs further validation. In this study, we investigated the
impact of KRAS codons 12 and 13, and BRAF mutations on survival from CRC, overall and stratified by sex, in a large
prospective cohort study.
Methods: KRAS codons 12 and 13, and BRAF mutations were analysed by pyrosequencing of tumours from 525
and 524 incident CRC cases in The Malmö Diet and Cancer Study. Associations with cancer-specific survival (CSS)
were explored by Cox proportional hazards regression, unadjusted and adjusted for age, TNM stage, differentiation
grade, vascular invasion and microsatellite instability (MSI) status.
Results: KRAS and BRAF mutations were mutually exclusive. KRAS mutations were found in 191/ 525 (36.4%) cases,
82.2% of these mutations were in codon 12, 17.3% were in codon 13, and 0.5% cases had mutations in both
codons. BRAF mutations were found in 78/524 (14.9%) cases. Overall, mutation in KRAS codon 13, but not codon
12, was associated with a significantly reduced CSS in unadjusted, but not in adjusted analysis, and BRAF mutation
did not significantly affect survival. However, in microsatellite stable (MSS), but not in MSI tumours, an adverse
prognostic impact of BRAF mutation was observed in unadjusted, but not in adjusted analysis. While KRAS
mutation status was not significantly associated with sex, BRAF mutations were more common in women. BRAF
mutation was not prognostic in women; but in men, BRAF mutation was associated with a significantly reduced
CSS in overall adjusted analysis (HR = 3.50; 95% CI = 1.41–8.70), but not in unadjusted analysis. In men with MSS
tumours, BRAF mutation was an independent factor of poor prognosis (HR = 4.91; 95% CI = 1.99–12.12). KRAS
codon 13 mutation was associated with a significantly reduced CSS in women, but not in men in unadjusted, but
not in adjusted analysis.
Conclusions: Results from this cohort study demonstrate sex-related differences in the prognostic value of BRAF
mutations in colorectal cancer, being particularly evident in men. These findings are novel and merit further
validation.
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The successful treatment of colorectal cancer (CRC) re-
lies on an early diagnosis, radical surgery and adequate
adjuvant treatment. Presently, tumour stage at diagnosis
is the most important prognostic factor. However, it is
becoming increasingly clear that CRC is a highly hete-
rogeneous disease with different genetic and molecular
characteristics affecting intrinsic tumour aggressiveness,
response to systemic treatment, and, hence, clinical out-
come. Although many efforts have been made to find
biomarkers to more accurately predict high-risk disease
and to select patients for adjuvant treatment, none have
proven good enough for use in clinical routine.
Activating mutations of proto-oncogenes KRAS and
BRAF are common in CRC, causing unregulated down-
stream signalling in the Ras/Raf/MEK/MAP signal trans-
duction pathway, in turn, affecting a variety of cellular
responses such as proliferation, differentiation, migration,
survival and apoptosis [1]. Approximately 40% of all colo-
rectal tumours harbour a KRAS mutation, predominantly
occurring in codon 12 or 13 [2]. While KRAS mutation
has proven to be predictive of the resistance to epidermal
growth factor receptor (EGFR)-inhibiting therapies [3,4],
the prognostic value of KRAS mutation in CRC remains
unclear. Numerous studies have investigated the relation-
ship between KRAS mutation status and survival from
CRC with divergent results; however, the majority of them
are associating KRAS mutation with a poor prognosis
[5-11]. Notably, while most studies did not consider spe-
cific mutations, accumulating evidence indicates that spe-
cific codon 12 and 13 mutations have a stronger impact
on the functionality of the KRAS protein, and, hence, its
impact on clinical outcome in CRC patients [5,12,13].
BRAF mutations have been reported in CRC at a fre-
quency of 5%–18% with the vast majority being a V600E
substitution [14]. BRAF mutation has also been linked to
an impaired prognosis in CRC [9,15,16] and unresponsive-
ness to anti-EGFR drugs [17-19]. BRAF and KRAS muta-
tions are, with rare exceptions, mutually exclusive [20].
The prognostic value of clinicopathological factors
[21,22] and investigative biomarkers [23] may well differ
in men and women, but to our best knowledge, no pre-
vious studies have investigated sex-related differences in
the prognostic impact of KRAS and BRAF mutation in
CRC. In the present study, we examined the associations
of specific KRAS and BRAF mutations with clinicopath-
ological and tumour biological characteristics, and sur-
vival, in 525 incident cases of colorectal cancer from a
prospective population-based cohort study.
Methods
Study population
Until the end of follow-up in 31 December 2008, 626 inci-
dent cases of CRC had been registered in the prospectivepopulation-based cohort from the Malmö Diet and Cancer
Study (MDCS) [22,24]. Patient and tumour characteristics
of the cohort have been described in detail previously
[23,25-27]. Ethical permission was obtained from the Eth-
ics Committee at Lund University. Tissue microarrays have
been constructed from 557 cases as previously described
[23,25]. Immunohistochemical analysis of mismatch repair
proteins MLH1, PMS2, MSH2 and MSH6 for the assess-
ment of microsatellite instability (MSI) status has been de-
scribed in [26], analysis of beta-catenin overexpression in
[27], of cyclin D1 in [23], and p21, p27 and p53 in [28].
Analysis of KRAS and BRAF mutation status
The PyroMark Q24 system (Qiagen GmbH, Hilden,
Germany) was used for pyrosequencing analysis of KRAS
and BRAF mutations in DNA from 1 mm formalin-fixed,
paraffin-embedded tumour tissue cores taken from areas
with >90% tumour cells. In brief, genomic DNA was
extracted from tumour tissue using QIAamp MinElute
spin columns (Qiagen) and DNA regions of interest were
PCR-amplified (Veriti 96-Well Fast Thermal Cycler, Ap-
plied Biosystems Inc., Foster City, CA, USA). KRAS co-
dons 12 and 13 were analysed using Therascreen KRAS
Pyro Kit (Qiagen). Analysis of BRAF mutation hotspots in
codons 600 and 601 was performed using previously pub-
lished PCR primers [29] and a novel BRAF sequencing
primer (5′-TGATTTTGGTCTAGCTACA-3′) which was
designed using the PyroMark Assay Design 2.0 software
(Qiagen). All samples with a potential low-level mutation
were reanalysed.
Statistical analysis
Associations between KRAS and BRAF mutation status
and clinicopathological factors were explored by Pearson's
Chi-square test. Kaplan-Meier analysis and log rank test
were performed to illustrate the differences in cancer-
specific survival (CSS). Cox proportional hazards regres-
sion was used for estimation of hazard ratio (HR) for
death from CRC. A backward conditional method was
used for variable selection in the multivariable model in-
cluding age, gender, T stage, N stage, M stage, differenti-
ation grade, vascular invasion, MSI status, and KRAS and
BRAF mutation status. The interaction between investiga-
tive factors and sex was explored by a Cox model includ-
ing the interaction variable. All survival analyses were
repeated with overall mortality as endpoint and all tests
were two-sided. A p value of 0.05 was considered signifi-
cant. All statistical analyses were performed using IBM
SPSS Statistics version 20.0.
Results
Distribution of KRAS and BRAF mutations
KRAS and BRAF mutations were successfully evaluated
in 525 and 524 cases, respectively. The distribution of
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number of 334 (63.7%) tumours were KRAS wild-type
and 191 (36.4%) were KRAS-mutated. Specifically, 156
(29.8%) cases harboured a KRAS codon 12 mutation, 34
(6.5%) a KRAS codon 13 mutation and 1 case (0.2%) had
dual codons 12 and 13 mutations. The distribution of
specific KRAS mutations did not differ between sexes
(data not shown). KRAS and BRAF mutations were mu-
tually exclusive. Further, 446 (85.1%) of the tumours
were BRAF wild-type, 76 (14.5%) were BRAF V600E-
mutated and 2 (0.4%) were BRAF K601E-mutated with a
total of 78 (14.9%) cases harbouring a BRAF mutation.Correlations of KRAS and BRAF mutations with
clinicopathological and tumour biological parameters
As shown in Table 2, there was a significant association
between KRAS wild-type tumours and MSI. Further,
KRAS codon 13 mutation correlated with metastatic dis-
ease (M1) and p27 negativity. Notably, when KRAS codon
12-mutated tumours were compared with tumours being
either KRAS wild-type or codon 13-mutated, there was a
significantly higher proportion of mucinous tumours in
the former category (p = 0.032 and p = 0.024).
BRAF mutation was significantly associated with older
age, female sex, proximal tumour location, low differenti-
ation grade, mucinous tumour type, MSI and expression
of cyclin D1, and inversely associated with beta-catenin
overexpression, p53 positivity and p27 expression.Prognostic significance of KRAS and BRAF mutations
Hazard ratios for CSS according to KRAS and BRAF muta-
tion status in the entire cohort, and strata according to sex,
are shown in Table 3. In the entire cohort, a similar survival
was seen for patients with KRAS wild-type and codon 12-
mutated tumours, while patients with tumours harbouring
a KRAS codon 13 mutation had a significantly reduced
CSS (HR = 1.94; 95% CI = 1.18–3.19) in unadjusted, but
not in adjusted analysis. KRAS codon 13, but not codon 12,
mutation was also significantly associated with poor prog-
nosis in women (HR = 2.58; 95% CI = 1.31–5.09) inTable 1 Distribution of KRAS mutations in 191 cases
Codon Sequence (amino acid) Number (%)
12 CGT (Arg) 2 (1.0)
GAT (Asp) 57 (29.8)
GTT (Val) 60 (31.4)
TGT (Cys) 15 (7.9)
AGT (Ser) 13 (6.8)
GCT (Ala) 10 (5.2)
13 GAC (Asp) 33 (17.3)
GTC (Val) 1 (0.5)unadjusted, but not in adjusted analysis. The KRAS muta-
tion status was not prognostic in men.
There were no significant associations of BRAF muta-
tion with CSS in the entire cohort or in women, neither
in unadjusted nor in adjusted analysis. In men, BRAF
mutation was not prognostic in unadjusted, but in ad-
justed analysis (HR = 3.50; 95% CI = 1.41–8.70). This
finding led us to investigate whether the prognostic
value of BRAF differs in different disease stages in men
and women and found that BRAF status was particularly
prognostic in lymph node-positive disease in men, but
not in women (data not shown).
Specific point mutations in KRAS codon 12 or 13 had
no significant impact on survival, neither in the entire
cohort nor in strata according to gender (data not
shown). Similar results were observed for the overall
survival (data not shown). KRAS and BRAF mutation
status did not predict response to standard adjuvant
chemotherapy in curatively treated patients with stages
III and IV disease (data not shown).
Prognostic value of BRAF mutation according to MSI
status
As BRAF mutation has been previously reported to be
associated with a particularly poor survival in cases with
microsatellite stable (MSS) tumours [8,15,30,31], we also
examined whether the prognostic value of BRAF muta-
tion differs by MSI status, overall and stratified for sex.
As shown in Table 4, BRAF mutation was overall associ-
ated with a significantly shorter CSS in patients with
MSS tumours in unadjusted analysis (HR = 2.36; 95%
CI = 1.44–3.86) and borderline significant in adjusted
analysis (HR = 1.80; 95% CI = 0.98–3.28). BRAF mu-
tation was not prognostic in MSI tumours. Again, no
prognostic significance was found for BRAF mutation in
women, either in MSS or in MSI tumours. In men,
BRAF mutation was an independent factor of poor prog-
nosis in MSS tumours (unadjusted HR = 3.46, 95%
CI = 1.78–6.74; adjusted HR = 4.91, 95% CI = 1.99–
12.12). Adjusted analysis was not performed in MSI tu-
mours due to the small subgroups.
Discussion
In this study, we have investigated the prognostic signifi-
cance of KRAS codons 12 and 13, and BRAF mutations
in incident colorectal cancer from a large prospective
cohort study, with particular reference to sex-related dif-
ferences. As regards to the KRAS mutation status, the
results demonstrated a significant association of KRAS
codon 13 mutation, but not codon 12, with poor prog-
nosis, but this significance was not retained in adjusted
analysis. These results support precious findings by
Bazan et al. who reported KRAS codon 13 mutation to
be an independent predictor of a poor prognosis [5].
Table 2 Associations of KRAS codons 12 and 13, and BRAF mutation status with clinicopathological and molecular
characteristics
KRAS wild-type Codon 12-mutated Codon 13-mutated p value BRAF wild-type BRAF-mutated p value
334 (63.7)a 156 (29.8)a 34 (6.5)a 446 (85.1)a 78 (14.9)a
Age
Mean, median 70.5, 71.4 70.9, 71.4 68.5, 69.6 0.297b 70.2, 70.8 72.0, 73.1 0.017b
Range 51.5–85.6 50.9–84.0 49.8–83.7 49.8–86.6 51.5–84.3
Sex
Female 177 (53.0) 83 (53.2) 18 (52.9) 0.999 227 (50.9) 50 (64.1) 0.031
Male 157 (47.0) 73 (46.8) 16 (47.1) 219 (49.1) 28 (35.9)
Tumour location
Proximal 101 (30.4) 54 (34.6) 10 (29.4) 0.058 106 (23.8) 59 (77.6) <0.001
Transverse 18 (5.4) 0 (0) 3 (8.8) 11 (2.5) 10 (13.2)
Descending 15 (4.5) 12 (7.7) 1 (2.9) 24 (5.4) 4 (5.3)
Sigmoid 66 (19.9) 38 (24.4) 7 (20.6) 110 (24.7) 1 (1.3)
Rectum 132 (39.8) 52 (33.3) 13 (38.2) 195 (43.7) 2 (2.6)
Missing 2 - - 0 2
T stage
1 32 (10.0) 9 (6.0) 4 (13.3) 0.291 42 (9.9) 3 (4.1) 0.001
2 38 (11.9) 18 (11.9) 2 (6.7) 52 (12.2) 6 (8.1)
3 201 (63.0) 104 (68.9) 16 (53.3) 278 (65.3) 43 (58.1)
4 48 (15.0) 20 (13.2) 8 (26.7) 54 (12.7) 22 (29.7)
Missing 15 5 4 20 4
N stage
0 180 (59.6) 84 (57.9) 15 (51.7) 0.710 241 (59.7) 37 (51.4) 0.353
1 69 (22.8) 39 (26.9) 7 (24.1) 97 (24.0) 19 (26.4)
2 53 (17.5) 22 (15.2) 7 (24.1) 66 (16.3) 16 (22.2)
Missing 32 12 5 42 6
M stage
0 275 (84.1) 128 (82.6) 22 (64.7) 0.018 366 (83.0) 59 (78.7) 0.363
1 52 (15.9) 27 (17.4) 12 (35.3) 75 (17.0) 16 (21.3)
Missing 17 1 - 5 3
Differentiation grade
High 20 (6.2) 11 (7.1) 0 (0) 0.088 25 (5.7) 5 (6.8) <0.001
Intermediate 222 (68.7) 121 (77.6) 26 (76.5) 340 (77.4) 30 (40.5)
Low 81 (25.1) 24 (15.4) 8 (23.5) 74 (16.9) 39 (52.7)
Missing 11 - - 7 4
Vascular invasion
No 95 (51.1) 45 (47.4) 7 ( 38.9) 0.561 125 (49.4) 21 (46.7) 0.735
Yes 91 (48.9) 50 (52.6) 11 (61.1) 128 (50.6) 24 (53.3)
Missing 148 61 16 193 33
Tumour type
Non-mucinous 269 (82.0) 114 (73.5) 28 (84.8) 0.073 360 (81.8) 50 (65.8) 0.001
Mucinous 59 (18.0) 41 (26.5) 5 (15.2) 80 (18.2) 26 (34.2)
Missing 6 1 1 6 2
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Table 2 Associations of KRAS codons 12 and 13, and BRAF mutation status with clinicopathological and molecular
characteristics (Continued)
MSI screening status
MSS 245 (79.3) 137 (96.5) 31 (93.9) <0.001 384 (93.2) 29 (40.3) <0.001
MSI 64 (20.7) 5 (3.5) 2 (6.1) 28 (6.8) 43 (59.7)
Missing 25 14 1 24 6
Beta-catenin grades
0–1 94 (29.7) 37 (25.0) 13 (38.2) 0.470 99 (23.4) 45 (59.2) <0.001
2–3 108 (34.1) 48 (32.4) 9 (26.5) 138 (32.6) 26 (34.2)
4–5 115 (36.3) 63 (42.6) 12 (35.3) 186 (44.0) 5 (6.6)
Missing 17 8 - 23 2
p53 status
Negative 169 (53.1) 77 (51.3) 12 (37.5) 0.240 202 (47.6) 57 (75.0) <0.001
Positive 149 (46.9) 73 (48.7) 20 (62.5) 222 (52.4) 19 (25.0)
Missing 16 6 2 22 2
p21 Expression
Negative 43 (13.7) 22 (14.9) 5 (15.2) 0.931 63 (15.0) 7 (9.2) 0.180
Positive 271 (86.3) 126 (85.1) 28 (84.8) 356 (85.0) 69 (90.8)
Missing 20 8 1 27 2
p27 Expression
Negative 58 (18.4) 15 (10.1) 9 (27.3) 0.018 51 (12.1) 31 (40.8) <0 001
Positive 258 (81.6) 134 (89.9) 24 (72.7) 371 (87.9) 45 (59.2)
Missing 18 7 1 24 2
Cyclin D1 expression
Negative 63 (20.0) 23 (15.4) 10 (30.3) 0.129 90 (21.4) 5 (6.6) 0.003
Positive 252 (80.0) 126 (84.6) 23 (69.7) 331 (78.6) 71 (93.4)
Missing 19 7 1 25 2
an (%); bKruskal-Wallis or Mann–Whitney U test. MSI microsatellite unstable, MSS microsatellite stable. One case with mutual codons 12 and 13 mutation was
excluded from the analyses related to KRAS mutational status.
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but only borderline significant [13]. Other studies have
further reported any KRAS mutation to be associated
with poor outcome [6-8,32]. In the present study, sub-
group analysis revealed that KRAS codon 13 mutation
was only prognostic in women and not in men, but only
in unadjusted analysis. While no significant associations
were found between KRAS mutations and sex, the sig-
nificant association of KRAS mutation with MSS tu-
mours found here is in concordance with the results
from previous studies [6,7,9]. Further, the associations
of KRAS codon 13 mutation with metastatic disease and
codon 12 mutation with mucinous tumour type have
also been demonstrated previously [5]. Taken together,
these findings further indicate that specific KRAS codon
mutations have different impact on protein functionality
and should be taken into consideration when evaluating
KRAS mutation status in the clinical setting. Further-
more, in light of the accentuated prognostic impact of
KRAS codon 13 mutation in women, it will also be ofinterest to perform further studies on the associations of
hormonal factors with KRAS mutation status in CRC.
In analysis of the entire cohort, BRAF mutation was
not prognostic in women, but in men; BRAF mutation
was significantly associated with an impaired survival in
adjusted, but not in unadjusted analysis. This may be
explained by the fact that the prognostic impact of
BRAF mutation status was stronger in, e.g. lymph node-
positive disease in men, but not in women. It is well
established that BRAF mutation, in contrast to KRAS
mutation, is associated with MSI [9,10,16,33] and female
sex [10,33,34], and our findings further validate this. In
MSS tumours, BRAF mutation was significantly asso-
ciated with a reduced CSS in unadjusted analysis, and
was borderline significant in adjusted analysis. These
findings are in concordance with several previous stud-
ies [9,15,17,35], indicating that BRAF-mutated/MSS tu-
mours represent a more aggressive tumour phenotype.
However, the results from this study further demonstrate
that BRAF-mutated/MSS tumours were not significantly
Table 3 Risk of death from colorectal cancer according to KRAS codons 12 and 13, and BRAF mutations
Entire cohort Women Men
HR (95% CI) n (events) HR (95% CI) n (events) HR (95% CI) n (events)
KRAS status (unadjusted)
Wild-type 1.00 334 (113) 1.00 177 (52) 1.00 157 (61)
Codon 12-mutated 1.05 (0.76–1.45) 156 (54) 1.32 (0.85–2.05) 83 (32) 0.81 (0.50–1.32) 73 (22)
Codon 13-mutated 1.94 (1.18–3.19) 34 (18) 2.58 (1.31–5.09) 18 (10) 1.42 (0.68–2.96) 16 (8)
KRAS status (adjusted)
Wild-type 1.00 273 (87) 1.00 146 (39) 1.00 127 (65)
Codon 12-mutated 1.02 (0.69–1.51) 132 (44) 1.29 (0.75–2.22) 67 (24) 0.74 (0.42–1.30) 65 (20)
Codon 13-mutated 1.37 (0.74–2.54) 28 (13) 1.83 (0.79–4.23) 15 (7) 0.87 (0.34–2.72) 13 (6)
BRAF status (unadjusted)
Wild-type 1.00 446 (154) 1.00 227 (75) 1.00 219 (79)
Mutated 1.32 (0.90–1.94) 78 (32) 1.23 (0.74–2.04) 50 (19) 1.56 (0.87–2.81) 28 (13)
BRAF status (adjusted)
Wild-type 1.00 370 (122) 1.00 184 (56) 1.00 186 (66)
Mutated 1.56 (0.87–2.79) 63 (22) 1.47 ( 0.65–3.33) 44 (14) 3.50 (1.41–8.70) 19 (8)
Adjusted analysis included age (continuous), sex, T stage (I-II, III, IV), N stage (0, 1, 2), M stage (0, 1), differentiation grade (high-intermediate vs. low and vascular
invasion (+/−/unknown)), KRAS mutation status (wild-type, codon 12 mutation, codon 13 mutation) and BRAF mutation status (wild-type, mutated). One case with
mutual KRAS codons 12 and 13 mutation was excluded from the analyses related to KRAS mutational status.
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pendent predictor of a reduced CSS in men.
To date, no biomarkers have yet been incorporated into
clinical protocols for prognostication and treatment strati-
fication of CRC patients in the adjuvant setting, which still
relies entirely on the assessment of conventional clinico-
pathological factors and patient performance. Approxi-
mately 20% of patients with stage II disease will develop
recurrent disease and although several risk factors, e.g.
<12 examined lymph nodes, T4 disease, vascular or neuralTable 4 Risk of death from colorectal cancer according to BRA
Entire cohort
HR (95% CI) n (events)
BRAF status-MSS tumours (unadjusted)
Wild-type 1.00 384 (135)
Mutated 2.36 (1.44–3.86) 29 (18)
BRAF status-MSI tumours (unadjusted)
Wild-type 1.00 28 (4)
Mutated 1.68 (0.53–5.36) 43 (10)
BRAF status-MSS tumours (adjusted)
Wild-type 1.00 343 (118)
Mutated 1.80 (0.98–3.28) 23 (14)
BRAF status-MSI tumours (adjusted)
Wild-type 1.00 27 (4)
Mutated 3.24 (0.39–26.92) 40 (8)
Adjusted analysis included age (continuous), sex, T stage (I-II, III, IV), N stage (0,1,2),
invasion (+/−/unknown)) and KRAS mutation status (wild-type, codon 12 mutation,
was excluded from the adjusted analysis.invasion, low differentiation, acute operation and tumour
perforation, have been suggested, the benefit from adju-
vant chemotherapy in this patient category is rather mod-
est [36,37]. Our results further indicate that this algorithm
is not only in need of additional molecular biomarkers,
but that sex should also be included as a variable.
The main purpose of this study was to analyse and
compare the prognostic significance of KRAS and BRAF
mutations in women and men, irrespective of adjuvant
treatment. However, potential differences in response toF mutation and by microsatellite instability status
Women Men
HR (95% CI) n (events) HR (95% CI) n (events)
1.00 194 (64) 1.00 190 (71)
1.73 (0.83–3.61) 16 (8) 3.46 (1.78–6.74) 13 (10)
1.00 16 (2) 1.00 12 (2)
2.15 (0.46–10.12) 31 (8) 1.03 (0.14–7.31) 12 (2)
1.00 169 (54) 1.00 174 (64)
1.37 (0.56–3.35) 14 (7) 4.91 (1.99–12.12) 9 (7)
- - - -
- - - -
M stage (0, 1), differentiation grade (high-intermediate vs. low and vascular
codon 13 mutation). One case with mutual KRAS codons 12 and 13 mutation
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tients with stages III and IV disease according to KRAS
and BRAF mutational status, MSI status and sex were also
examined, whereby no significant differences were found.
Therefore, the finding of BRAF mutation being a particu-
larly negative prognostic factor in men warrants validation
in additional independent patient cohorts, which may well
be done in the retrospective setting, before further pro-
spective study.
Although the proportion of patients in this study that
may have received EGFR inhibitors upon recurrent disease
is likely to be negligible, it is also important to consider
potential sex differences when evaluating the results from
trials related to response to EGFR inhibitors. For instance,
results from several trials have demonstrated a signifi-
cantly better response to EGFR tyrosine kinase inhibitors
in women with advanced non-small cell lung cancer com-
pared to men [38,39].
The higher prevalence of BRAF-mutated tumours in
women, together with the lack of prognostic impact of
BRAF mutations in female CRC, indicates the possibility
of a link between hormonal factors and BRAF mutation
status in CRC. Therefore, an influence of anthropomet-
ric and lifestyle factors is also plausible [22] and should
be pursued in future studies.
As a cautionary remark, several of the here presented re-
sults, in particular related to gender, are derived from ana-
lyses of rather small subgroups and need validation in
additional patient cohorts. The validity of the findings are
however strengthened by the expected associations of
KRAS and BRAF mutations with clinicopathological fac-
tors, e.g. KRAS and BRAF mutations being mutually exclu-
sive [20], the significant associations between BRAF
mutation, MSI [15,20,40] and mucinous phenotype [41,42].
Apart from established clinicopathological parameters,
we have also examined associations of KRAS and BRAF
mutation status with several other investigative factors, i.e.
beta-catenin overexpression and expression of p53, p21,
p27 and cyclin D1. The observed inverse association be-
tween BRAF mutation and beta-catenin overexpression
has been described earlier [43,44] and is also in line with
the previous findings of beta-catenin overexpression being
associated with good prognosis in this cohort [28]. The
observed associations between BRAF mutation and ex-
pression of p21 and cyclin D1, and loss of p27 and p53 ex-
pression have also been previously reported [45-48].
The Malmö Diet and Cancer Study is a population-
based cohort study, wherein a potential selection bias
compared with the general population must be taken into
consideration. As previously denoted [23], the frequency
of emergency surgery was only 8.3% which is lower
than the commonly reported frequency of approximately
25% [49,50], which may reflect a higher awareness of
CRC among study participants. On the other hand, thedistribution of clinical stages at diagnosis is in line with
the expected [23,25].
Conclusions
In conclusion, the results from this large prospective co-
hort study provide further support to the accumulating
evidence of BRAF-mutated microsatellite stable colorec-
tal cancer having a particularly impaired prognosis. The
finding of BRAF mutation being an independent factor
of poor prognosis in male, but not in female colorectal
cancer, both overall and in MSS tumours, is however
novel and merits further study. Moreover, the findings in
this study further emphasize the importance of taking
sex into consideration in all cancer biomarker studies,
since this may enable the development of more accurate
prognostic nomograms for identification of patients with
high-risk disease.
Competing interests
The authors declare no competing interests.
Authors’ contributions
SW carried out the statistical analyses and drafted the manuscript. BN,
NZ and MS carried out the pyrosequencing analyses and helped draft the
manuscript. KEL carried out some of the immunohistochemical analyses.
SW and JE collected the clinical data. JE and KJ conceived of the study,
participated in its design and coordination and helped to draft the
manuscript. All authors read and approved the final manuscript.
Acknowledgements
This work was supported by the Swedish Cancer Society, The Gunnar Nilsson
Cancer Foundation, Region Skåne and the Research Funds of Skåne
University Hospital to KJ, and The Olle Engkvist Foundation, Anna Lisa and
Sven-Eric Lundgren Foundation and Crafoord Foundation to JE.
Author details
1Department of Clinical Sciences, Division of Pathology, Lund University,
Lund, Sweden. 2Department of Immunology, Genetics and Pathology,
Uppsala University, Uppsala, Sweden. 3Department of Clinical Sciences,
Division of Oncology, Lund University, Lund, Sweden.
Received: 13 August 2013 Accepted: 30 August 2013
Published: 10 September 2013
References
1. McCubrey JA, Steelman LS, Abrams SL, Lee JT, Chang F, Bertrand FE,
Navolanic PM, Terrian DM, Franklin RA, D'Assoro AB, Salisbury JL, Mazzarino
MC, Stivala F, Libra M: Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT
pathways in malignant transformation and drug resistance. Adv Enzyme
Regul 2006, 46:249–279.
2. Arrington AK, Heinrich EL, Lee W, Duldulao M, Patel S, Sanchez J, Garcia-
Aguilar J, Kim J: Prognostic and predictive roles of KRAS mutation in
colorectal cancer. Int J Mol Sci 2012, 13(10):12153–12168.
3. De Roock W, Piessevaux H, De Schutter J, Janssens M, De Hertogh G,
Personeni N, Biesmans B, Van Laethem JL, Peeters M, Humblet Y, Van
Cutsem E, Tejpar S: KRAS wild-type state predicts survival and is
associated to early radiological response in metastatic colorectal cancer
treated with cetuximab. Ann Oncol 2008, 19(3):508–515.
4. Allegra CJ, Jessup JM, Somerfield MR, Hamilton SR, Hammond EH, Hayes DF,
McAllister PK, Morton RF, Schilsky RL: American society of clinical oncology
provisional clinical opinion: testing for KRAS gene mutations in patients
with metastatic colorectal carcinoma to predict response to anti-
epidermal growth factor receptor monoclonal antibody therapy.
J Clin Oncol 2009, 27(12):2091–2096.
5. Bazan V: Specific codon 13 K-ras mutations are predictive of clinical
outcome in colorectal cancer patients, whereas codon 12 K-ras
Wangefjord et al. Biology of Sex Differences 2013, 4:17 Page 8 of 9
http://www.bsd-journal.com/content/4/1/17mutations are associated with mucinous histotype. Ann Oncol 2002,
13(9):1438–1446.
6. Nash GM, Gimbel M, Cohen AM, Zeng ZS, Ndubuisi MI, Nathanson DR, Ott
J, Barany F, Paty PB: KRAS mutation and microsatellite instability: two
genetic markers of early tumor development that influence the
prognosis of colorectal cancer. Ann Surg Oncol 2010, 17(2):416–424.
7. Hutchins G, Southward K, Handley K, Magill L, Beaumont C, Stahlschmidt J,
Richman S, Chambers P, Seymour M, Kerr D, Gray R, Quirke P: Value of
mismatch repair, KRAS, and BRAF mutations in predicting recurrence
and benefits from chemotherapy in colorectal cancer. J Clin Oncol 2011,
29(10):1261–1270.
8. Phipps AI, Buchanan DD, Makar KW, Win AK, Baron JA, Lindor NM, Potter JD,
Newcomb PA: KRAS-mutation status in relation to colorectal cancer
survival: the joint impact of correlated tumour markers. Br J Cancer 2013,
108(8):1757–1764.
9. Ogino S, Nosho K, Kirkner GJ, Kawasaki T, Meyerhardt JA, Loda M,
Giovannucci EL, Fuchs CS: CpG island methylator phenotype,
microsatellite instability, BRAF mutation and clinical outcome in colon
cancer. Gut 2009, 58(1):90–96.
10. Roth AD, Tejpar S, Delorenzi M, Yan P, Fiocca R, Klingbiel D, Dietrich D,
Biesmans B, Bodoky G, Barone C, Aranda E, Nordlinger B, Cisar L, Labianca R,
Cunningham D, Van Cutsem E, Bosman F: Prognostic role of KRAS and
BRAF in stage II and III resected colon cancer: results of the translational
study on the PETACC-3, EORTC 40993, SAKK 60–00 trial. J Clin Oncol
2010, 28(3):466–474.
11. Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC,
Simes RJ, Chalchal H, Shapiro JD, Robitaille S, Price TJ, Shepherd L, Au HJ,
Langer C, Moore MJ, Zalcberg JR: K-ras mutations and benefit from
cetuximab in advanced colorectal cancer. N Engl J Med 2008,
359(17):1757–1765.
12. Zlobec I, Kovac M, Erzberger P, Molinari F, Bihl MP, Rufle A, Foerster A,
Frattini M, Terracciano L, Heinimann K, Lugli A: Combined analysis of
specific KRAS mutation, BRAF and microsatellite instability identifies
prognostic subgroups of sporadic and hereditary colorectal cancer.
Int J Cancer 2010, 127(11):2569–2575.
13. Samowitz WS, Curtin K, Schaffer D, Robertson M, Leppert M, Slattery ML:
Relationship of Ki-ras mutations in colon cancers to tumor location,
stage, and survival: a population-based study. Cancer Epidemiol Biomarkers
Prev 2000, 9(11):1193–1197.
14. Safaee Ardekani G, Jafarnejad SM, Tan L, Saeedi A, Li G: The prognostic
value of BRAF mutation in colorectal cancer and melanoma: a
systematic review and meta-analysis. PLoS One 2012, 7(10):e47054.
15. Samowitz WS, Sweeney C, Herrick J, Albertsen H, Levin TR, Murtaugh MA,
Wolff RK, Slattery ML: Poor survival associated with the BRAF V600E
mutation in microsatellite-stable colon cancers. Cancer Res 2005,
65(14):6063–6069.
16. Farina-Sarasqueta A, van Lijnschoten G, Moerland E, Creemers GJ, Lemmens
VE, Rutten HJ, van den Brule AJ: The BRAF V600E mutation is an
independent prognostic factor for survival in stage II and stage III colon
cancer patients. Ann Oncol 2010, 21(12):2396–2402.
17. Di Nicolantonio F, Martini M, Molinari F, Sartore-Bianchi A, Arena S, Saletti P,
De Dosso S, Mazzucchelli L, Frattini M, Siena S, Bardelli A: Wild-type BRAF is
required for response to panitumumab or cetuximab in metastatic
colorectal cancer. J Clin Oncol 2008, 26(35):5705–5712.
18. Souglakos J, Philips J, Wang R, Marwah S, Silver M, Tzardi M, Silver J, Ogino
S, Hooshmand S, Kwak E, Freed E, Meyerhardt JA, Saridaki Z, Georgoulias V,
Finkelstein D, Fuchs CS, Kulke MH, Shivdasani RA: Prognostic and
predictive value of common mutations for treatment response and
survival in patients with metastatic colorectal cancer. Br J Cancer 2009,
101(3):465–472.
19. De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilas G,
Kalogeras KT, Kotoula V, Papamichael D, Laurent-Puig P, Penault-Llorca F,
Rougier P, Vincenzi B, Santini D, Tonini G, Cappuzzo F, Frattini M, Molinari F,
Saletti P, De Dosso S, Martini M, Bardelli A, Siena S, Sartore-Bianchi A, Tabernero
J, Macarulla T, Di Fiore F, Gangloff AO, Ciardiello F, Pfeiffer P, et al: Effects of
KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus
chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a
retrospective consortium analysis. Lancet Oncol 2010, 11(8):753–762.
20. Rajagopalan H, Bardelli A, Lengauer C, Kinzler KW, Vogelstein B, Velculescu
VE: Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status.
Nature 2002, 418(6901):934.21. Fridberg M, Jonsson L, Bergman J, Nodin B, Jirstrom K: Modifying effect of
gender on the prognostic value of clinicopathological factors and Ki67
expression in melanoma: a population-based cohort study. Biol Sex Differ
2012, 3(1):16.
22. Brandstedt J, Wangefjord S, Nodin B, Gaber A, Manjer J, Jirstrom K: Gender,
anthropometric factors and risk of colorectal cancer with particular
reference to tumour location and TNM stage: a cohort study. Biol Sex
Differ 2012, 3(1):23.
23. Wangefjord S, Manjer J, Gaber A, Nodin B, Eberhard J, Jirstrom K: Cyclin D1
expression in colorectal cancer is a favorable prognostic factor in men
but not in women in a prospective, population-based cohort study.
Biol Sex Differ 2011, 2:10.
24. Berglund G, Elmstahl S, Janzon L, Larsson SA: The malmo diet and cancer
study. design and feasibility. J Intern Med 1993, 233(1):45.
25. Larsson A, Johansson ME, Wangefjord S, Gaber A, Nodin B, Kucharzewska P,
Welinder C, Belting M, Eberhard J, Johnsson A, Uhlén M, Jirström K:
Overexpression of podocalyxin-like protein is an independent factor of
poor prognosis in colorectal cancer. Br J Cancer 2011, 105(5):666–672.
26. Eberhard J, Gaber A, Wangefjord S, Nodin B, Uhlen M, Ericson Lindquist K,
Jirstrom K: A cohort study of the prognostic and treatment predictive value
of SATB2 expression in colorectal cancer. Br J Cancer 2012, 106(5):931–938.
27. Nodin B, Johannesson H, Wangefjord S, O’Connor DP, Ericson-Lindquist K,
Uhlen M, Jirstrom K, Eberhard J: Molecular correlates and prognostic
significance of SATB1 expression in colorectal cancer. Diagn Pathol 2012,
7(1):115.
28. Wangefjord S, Brandstedt J, Ericson Lindquist K, Nodin B, Jirstrom K,
Eberhard J: Associations of beta-catenin alterations and MSI screening
status with expression of key cell cycle regulating proteins and survival
from colorectal cancer. Diagn Pathol 2013, 8(1):10.
29. Richman SD, Seymour MT, Chambers P, Elliott F, Daly CL, Meade AM, Taylor
G, Barrett JH, Quirke P: KRAS and BRAF mutations in advanced colorectal
cancer are associated with poor prognosis but do not preclude benefit
from oxaliplatin or irinotecan: results from the MRC FOCUS trial.
J Clin Oncol 2009, 27(35):5931–5937.
30. Kakar S, Deng G, Sahai V, Matsuzaki K, Tanaka H, Miura S, Kim YS:
Clinicopathologic characteristics, CpG island methylator phenotype, and
BRAF mutations in microsatellite-stable colorectal cancers without
chromosomal instability. Arch Pathol Lab Med 2008, 132(6):958–964.
31. Ogino S, Shima K, Meyerhardt JA, McCleary NJ, Ng K, Hollis D, Saltz LB,
Mayer RJ, Schaefer P, Whittom R, Hantel A, Benson AB 3rd, Spiegelman D,
Goldberg RM, Bertagnolli MM, Fuchs CS: Predictive and prognostic roles of
BRAF mutation in stage III colon cancer: results from intergroup trial
CALGB 89803. Clin Cancer Res 2012, 18(3):890–900.
32. Nakanishi R, Harada J, Tuul M, Zhao Y, Ando K, Saeki H, Oki E, Ohga T, Kitao
H, Kakeji Y, Maehara Y: Prognostic relevance of KRAS and BRAF mutations
in Japanese patients with colorectal cancer. Int J Clin Oncol 2012.
doi:10.1007/s10147-012-0501-x.
33. Kalady MF, Dejulius KL, Sanchez JA, Jarrar A, Liu X, Manilich E, Skacel M,
Church JM: BRAF mutations in colorectal cancer are associated with
distinct clinical characteristics and worse prognosis. Dis Colon Rectum
2012, 55(2):128–133.
34. Capper D, Voigt A, Bozukova G, Ahadova A, Kickingereder P, von Deimling
A, von Knebel DM, Kloor M: BRAF V600E-specific immunohistochemistry
for the exclusion of Lynch syndrome in MSI-H colorectal cancer. Int J
Cancer 2013, 133(7):1624–1630.
35. Bond CE, Umapathy A, Buttenshaw RL, Wockner L, Leggett BA, Whitehall VL:
Chromosomal instability in BRAF mutant, microsatellite stable colorectal
cancers. PLoS One 2012, 7(10):e47483.
36. Group QC: Adjuvant chemotherapy versus observation in patients with
colorectal cancer: a randomised study. Lancet 2007, 370(9604):2020–2029.
37. Figueredo A, Coombes ME, Mukherjee S: Adjuvant therapy for completely
resected stage II colon cancer. Cochrane Database Syst Rev 2008,
3, CD005390.
38. Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY,
Nishiwaki Y, Vansteenkiste J, Kudoh S, Rischin D, Eek R, Horai T, Noda K,
Takata I, Smit E, Averbuch S, Macleod A, Feyereislova A, Dong RP, Baselga J:
Multi-institutional randomized phase II trial of gefitinib for previously
treated patients with advanced non-small-cell lung cancer (The IDEAL 1
Trial) [corrected]. J Clin Oncol 2003, 21(12):2237–2246.
39. Kris MG, Natale RB, Herbst RS, Lynch TJ Jr, Prager D, Belani CP, Schiller JH,
Kelly K, Spiridonidis H, Sandler A, Albain KS, Cella D, Wolf MK, Averbuch SD,
Wangefjord et al. Biology of Sex Differences 2013, 4:17 Page 9 of 9
http://www.bsd-journal.com/content/4/1/17Ochs JJ, Kay AC: Efficacy of gefitinib, an inhibitor of the epidermal
growth factor receptor tyrosine kinase, in symptomatic patients with
non-small cell lung cancer: a randomized trial. JAMA 2003,
290(16):2149–2158.
40. Wang L, Cunningham JM, Winters JL, Guenther JC, French AJ, Boardman LA,
Burgart LJ, McDonnell SK, Schaid DJ, Thibodeau SN: BRAF mutations in
colon cancer are not likely attributable to defective DNA mismatch
repair. Cancer Res 2003, 63(17):5209–5212.
41. Ogino S, Brahmandam M, Cantor M, Namgyal C, Kawasaki T, Kirkner G,
Meyerhardt JA, Loda M, Fuchs CS: Distinct molecular features of colorectal
carcinoma with signet ring cell component and colorectal carcinoma
with mucinous component. Mod Pathol 2006, 19(1):59–68.
42. Li WQ, Kawakami K, Ruszkiewicz A, Bennett G, Moore J, Iacopetta B: BRAF
mutations are associated with distinctive clinical, pathological and
molecular features of colorectal cancer independently of microsatellite
instability status. Mol Cancer 2006, 5:2.
43. Morikawa T, Kuchiba A, Yamauchi M, Meyerhardt JA, Shima K, Nosho K,
Chan AT, Giovannucci E, Fuchs CS, Ogino S: Association of CTNNB1 (beta-
catenin) alterations, body mass index, and physical activity with survival
in patients with colorectal cancer. JAMA 2011, 305(16):1685–1694.
44. Kawasaki T, Nosho K, Ohnishi M, Suemoto Y, Kirkner GJ, Dehari R,
Meyerhardt JA, Fuchs CS, Ogino S: Correlation β-catenin localization with
cyclooxygenase-2 expression and CpG island methylator phenotype in
colorectal cancer. Neoplasia 2007, 9(7):569–577.
45. Ogino S, Kawasaki T, Kirkner GJ, Ogawa A, Dorfman I, Loda M, Fuchs CS:
Down-regulation of p21 (CDKN1A/CIP1) is inversely associated with
microsatellite instability and CpG island methylator phenotype (CIMP) in
colorectal cancer. J Pathol 2006, 210(2):147–154.
46. Ogino S, Nosho K, Irahara N, Kure S, Shima K, Baba Y, Toyoda S, Chen L,
Giovannucci EL, Meyerhardt JA, Fuchs CS: A cohort study of cyclin D1
expression and prognosis in 602 colon cancer cases. Clin Cancer Res 2009,
15(13):4431–4438.
47. Ogino S, Kawasaki T, Kirkner GJ, Yamaji T, Loda M, Fuchs CS: Loss of nuclear
p27 (CDKN1B/KIP1) in colorectal cancer is correlated with microsatellite
instability and CIMP. Mod Pathol 2007, 20(1):15–22.
48. Morikawa T, Kuchiba A, Liao X, Imamura Y, Yamauchi M, Qian ZR, Nishihara
R, Sato K, Meyerhardt JA, Fuchs CS, Ogino S: Tumor TP53 expression
status, body mass index and prognosis in colorectal cancer. Int J Cancer
2012, 131(5):1169–1178.
49. Sjo OH, Larsen S, Lunde OC, Nesbakken A: Short term outcome after
emergency and elective surgery for colon cancer. Colorectal Dis 2009,
11(7):733–739.
50. Pavlidis TE, Marakis G, Ballas K, Rafailidis S, Psarras K, Pissas D, Sakantamis AK:
Does emergency surgery affect resectability of colorectal cancer?
Acta Chir Belg 2008, 108(2):219–225.
doi:10.1186/2042-6410-4-17
Cite this article as: Wangefjord et al.: Sex differences in the prognostic
significance of KRAS codons 12 and 13, and BRAF mutations in
colorectal cancer: a cohort study. Biology of Sex Differences 2013 4:17.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
